NCT02992470

Crassostrea Gigas for Liver Health

Hydrolyzed Oyster Extract for Liver Health: a Randomized, Double-blind, Placebo-controlled Trial

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 96 (estimated)
• Sponsor: Korean Medicine Hospital of Pusan National University · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

This study aimed to observe whether a hydrolyzed oyster extract improves liver health in participants whose alanine transaminase (ALT) levels are1-3 fold above the normal. A total of 96 participants will be randomly allocated to active (oyster) or placebo group (1:1). Each group will receive 750 mg of oyster extract or placebo per day for 8 weeks. Primary outcome will be the change in ALT level and secondary outcomes will be; (1) ratios of participants with normal ALT, aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT); (2) the change in serum bilirubin; (3) the change in multi-dimensional fatigue inventory; (4) the changes in serum lipids; (5) the changes in antioxidant enzymes.

Conditions

• Nonalcoholic Fatty Liver

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Hydrolyzed oyster extract	1 tablet of oyster extract t.i.d. for 8 weeks
DIETARY_SUPPLEMENT	Placebo	1 tablet of maltodextrin t.i.d. for 8 weeks

Timeline

• Start date: 2016-12-01
• Primary completion: 2017-12-01
• First posted: 2016-12-14
• Last updated: 2016-12-14